Zhijie Wang

8.6k total citations · 3 hit papers
177 papers, 3.8k citations indexed

About

Zhijie Wang is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Zhijie Wang has authored 177 papers receiving a total of 3.8k indexed citations (citations by other indexed papers that have themselves been cited), including 125 papers in Oncology, 115 papers in Pulmonary and Respiratory Medicine and 38 papers in Cancer Research. Recurrent topics in Zhijie Wang's work include Lung Cancer Treatments and Mutations (91 papers), Cancer Immunotherapy and Biomarkers (57 papers) and Lung Cancer Research Studies (42 papers). Zhijie Wang is often cited by papers focused on Lung Cancer Treatments and Mutations (91 papers), Cancer Immunotherapy and Biomarkers (57 papers) and Lung Cancer Research Studies (42 papers). Zhijie Wang collaborates with scholars based in China, United States and Ethiopia. Zhijie Wang's co-authors include Jie Wang, Jianchun Duan, Hua Bai, Shuhang Wang, Tongtong An, Jun Zhao, Jie Wang, Minglei Zhuo, Meina Wu and Jie He and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Zhijie Wang

167 papers receiving 3.7k citations

Hit Papers

Use of Immunotherapy With Programmed Cell Death 1 vs Prog... 2019 2026 2021 2023 2019 2021 2021 50 100 150 200
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer
    2019 249 citations Jianchun Duan, Hua Bai et al. profile →
  2. Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non–Small-Cell Lung Cancer
    2021 246 citations Jie Wang, Zhijie Wang et al. profile →
  3. Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis
    2021 160 citations Zhuoran Yao, Hua Bai et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Zhijie Wang China 33 2.3k 1.9k 999 961 454 177 3.8k
Daniel S.W. Tan Singapore 34 1.8k 0.8× 1.9k 1.0× 1.3k 1.3× 965 1.0× 321 0.7× 159 4.1k
William Jacot France 34 2.7k 1.2× 1.4k 0.7× 1.1k 1.1× 1.2k 1.3× 433 1.0× 224 4.2k
Rafael Santana-Dávila United States 22 1.7k 0.7× 1.2k 0.6× 1.7k 1.7× 671 0.7× 283 0.6× 70 3.7k
Luís Manso Spain 22 1.9k 0.8× 1.6k 0.8× 710 0.7× 802 0.8× 170 0.4× 153 3.3k
María D. Lozano Spain 35 1.1k 0.5× 1.8k 0.9× 1.0k 1.0× 717 0.7× 459 1.0× 151 3.7k
Prudence A. Francis Australia 34 3.3k 1.4× 1.2k 0.6× 890 0.9× 1.5k 1.5× 632 1.4× 129 5.1k
Caicun Zhou China 36 3.6k 1.6× 3.4k 1.8× 1.6k 1.6× 957 1.0× 734 1.6× 209 5.6k
Tao Jiang China 41 3.2k 1.4× 2.7k 1.4× 1.7k 1.7× 1.0k 1.0× 871 1.9× 176 5.5k
Amanda J. Redig United States 22 1.5k 0.7× 1.5k 0.8× 1.2k 1.2× 648 0.7× 222 0.5× 39 3.1k
Wendy A. Cooper Australia 35 2.5k 1.1× 2.9k 1.6× 2.0k 2.0× 1.4k 1.4× 561 1.2× 131 5.7k

Countries citing papers authored by Zhijie Wang

Since Specialization
Citations

This map shows the geographic impact of Zhijie Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zhijie Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zhijie Wang more than expected).

Fields of papers citing papers by Zhijie Wang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zhijie Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zhijie Wang. The network helps show where Zhijie Wang may publish in the future.

Co-authorship network of co-authors of Zhijie Wang

This figure shows the co-authorship network connecting the top 25 collaborators of Zhijie Wang. A scholar is included among the top collaborators of Zhijie Wang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zhijie Wang. Zhijie Wang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Yang, Zhenlin, Bolun Zhou, Wei Guo, et al.. (2024). Genomic characteristics and immune landscape of super multiple primary lung cancer. EBioMedicine. 101. 105019–105019. 6 indexed citations
2.
Guan, Hongyu, et al.. (2023). The prevalence and county-level socioeconomic correlates of visual impairment and glasses ownership among rural students in Western China. Frontiers in Public Health. 11. 1069793–1069793. 5 indexed citations
3.
4.
5.
Zhang, Jixiong, Tongqing Liu, Junwei Wang, et al.. (2023). A simple but effective evaluation criterion for parameters optimization of EPO and its application to moisture insensitive prediction of soil organic matter. Chemometrics and Intelligent Laboratory Systems. 236. 104794–104794. 7 indexed citations
6.
Xu, Haiyan, Yaning Yang, Fei Xu, et al.. (2023). Influence of PD‐L1 expression on the efficacy of EGFR‐TKIs in EGFR‐mutant non‐small cell lung cancer. Thoracic Cancer. 14(24). 2327–2337. 8 indexed citations
7.
Sun, Boyang, Tian Qiu, Jianchun Duan, et al.. (2023). Detection of MET Polysomy by Next-generation Sequencing and Its Clinical Relevance for MET Inhibitors. Cancer Research Communications. 3(4). 532–539. 7 indexed citations
8.
Wang, Zhijie & Qian Liu. (2023). Development of novel prediction models for nodal and distant metastasis in G1 and G2 colorectal neuroendocrine tumors. International Journal of Colorectal Disease. 38(1). 37–37. 1 indexed citations
9.
Liu, Yutao, Jing Zhao, Yanan Wang, et al.. (2023). IMPACT: A web server for exploring immunotherapeutic predictive and cancer prognostic biomarkers. Clinical and Translational Medicine. 13(9). e1354–e1354. 5 indexed citations
10.
Liu, Lihui, Sini Li, Yan Qu, et al.. (2023). Ablation of ERO1A induces lethal endoplasmic reticulum stress responses and immunogenic cell death to activate anti-tumor immunity. Cell Reports Medicine. 4(10). 101206–101206. 30 indexed citations
11.
12.
Sun, Yiting, Hua Bai, Jianchun Duan, et al.. (2022). Blockade of STAT3/IL-4 overcomes EGFR T790M-cis-L792F-induced resistance to osimertinib via suppressing M2 macrophages polarization. EBioMedicine. 83. 104200–104200. 23 indexed citations
13.
Zhao, Jie, Hua Bai, Jianchun Duan, et al.. (2021). Therapeutic guidance of tumor mutation burden on immune checkpoint inhibitors in advanced non-small cell lung cancer: a systematic review and comprehensive meta-analysis. SHILAP Revista de lepidopterología. 2(1). 41–49. 3 indexed citations
14.
Liu, Lihui, Hua Bai, Chao Wang, et al.. (2021). Efficacy and Safety of First-Line Immunotherapy Combinations for Advanced NSCLC: A Systematic Review and Network Meta-Analysis. Journal of Thoracic Oncology. 16(7). 1099–1117. 92 indexed citations
15.
Han, Jiefei, Jianchun Duan, Hua Bai, et al.. (2019). TCR Repertoire Diversity of Peripheral PD-1+CD8+ T Cells Predicts Clinical Outcomes after Immunotherapy in Patients with Non–Small Cell Lung Cancer. Cancer Immunology Research. 8(1). 146–154. 177 indexed citations
16.
Wang, Zhijie, Hongmei Li, Liang Zhang, et al.. (2019). Combining structure- and property-based optimization to identify selective FLT3-ITD inhibitors with good antitumor efficacy in AML cell inoculated mouse xenograft model. European Journal of Medicinal Chemistry. 176. 248–267. 13 indexed citations
17.
Tian, Yanhua, Zhijie Wang, Xiaohui Liu, et al.. (2018). Prediction of Chemotherapeutic Efficacy in Non–Small Cell Lung Cancer by Serum Metabolomic Profiling. Clinical Cancer Research. 24(9). 2100–2109. 57 indexed citations
18.
Yu, Jiangyong, Shuhang Wang, Wei Zhao, et al.. (2018). Mechanistic Exploration of Cancer Stem Cell Marker Voltage-Dependent Calcium Channel α2δ1 Subunit-mediated Chemotherapy Resistance in Small-Cell Lung Cancer. Clinical Cancer Research. 24(9). 2148–2158. 47 indexed citations
19.
Wan, Rui, Zhijie Wang, J. Jack Lee, et al.. (2017). Comprehensive Analysis of the Discordance of EGFR Mutation Status between Tumor Tissues and Matched Circulating Tumor DNA in Advanced Non–Small Cell Lung Cancer. Journal of Thoracic Oncology. 12(9). 1376–1387. 34 indexed citations
20.
Wang, Yuyan, Li Liu, Jia Zhong, et al.. (2015). [Prognostic factors and response of chemotherapy including amrubicin in small cell lung cancer patients].. PubMed. 38(4). 261–6. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Daniel S.W. Tan Breakdown of academic impact, for papers by William Jacot Breakdown of academic impact, for papers by Rafael Santana-Dávila Breakdown of academic impact, for papers by Luís Manso Breakdown of academic impact, for papers by María D. Lozano Breakdown of academic impact, for papers by Prudence A. Francis Breakdown of academic impact, for papers by Caicun Zhou Breakdown of academic impact, for papers by Tao Jiang Breakdown of academic impact, for papers by Amanda J. Redig Breakdown of academic impact, for papers by Wendy A. Cooper
Rankless by CCL
2026